Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

F8INH
83102
FX13M
57302
anticoagulation management of VTE patients.
Interpretation: The interpretive report will include specimen information, assay information,
background information, and conclusions based on the test results (normal, heterozygous factor V [FV
Leiden], homozygous FV Leiden).
Reference Values:
Negative
Clinical References: 1. Nichols WL, Heit JA: Activated protein C resistance and thrombosis. Mayo
Clin Proc 1996;71:897-898 2. Dahlback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a
previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C:
prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-1008 3. Bertina
RM, Koeleman BP, Koster T, et al: Mutation in blood coagulation factor V associated with resistance to
activated protein C. Nature 1994;369:64-67 4. Grody WW, Griffin JH, Taylor AK, et al: American
college of medical genetics consensus statement on factor V Leiden mutation testing. Genet Med
2001;3:139-148 5. Press RD, Bauer KA, Kujovich JL, Heit JA: Clinical utility of factor V Leiden
(R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Path Lab Med
2002;126:1304-1318
Factor VIII Inhibitor Evaluation
Clinical Information: Factor VIII inhibitors are IgG antibodies directed against coagulation FVIII
that typically result in development of potentially life-threatening hemorrhage. These antibodies may
develop in 1 of 4 different patient populations: -Patients with congenital FVIII deficiency (hemophilia A)
in response to therapeutic infusions of factor VIII concentrate -Elderly nonhemophiliac patients (not
previously factor VIII deficient) -Women in postpartum period -Patients with other autoimmune illnesses
Useful For: Detecting the presence and titer of a specific factor inhibitor directed against coagulation
factor VIII
Interpretation: Normally, there is no inhibitor, (ie, negative result). If the screening assays indicate the
presence of an inhibitor, it will be quantitated and reported in Bethesda (or equivalent) units.
Reference Values:
FACTOR VIII ACTIVITY ASSAY
Adults: 55-200%
Normal, full-term newborn infants or healthy premature infants usually have normal or elevated factor
VIII.*
*See Pediatric Hemostasis References in Coagulation Studies in Special Instructions.
FACTOR VIII INHIBITOR SCREEN
Negative
BETHESDA TITER
0 Units
Clinical References: 1. Kasper CK: Treatment of factor VIII inhibitors. Prog Hemost Thromb
1989;9:57-86 2. Peerschke EI, Castellone DD, Ledford-Kraemer M, et al: Laboratory assessment of FVIII
inhibitor titer. Am J Clin Pathol 2009;131(4):552-558 3. Pruthi RK, Nichols WL: Autoimmune factor
VIII inhibitors. Curr Opin Hematol 1999;6(5):314-322
Factor XIII, Qualitative, with Reflex to Factor XIII 1:1 Mix
Reference Values:
Factor XIII, Qualitative: No Lysis
Factor XIII, 1:1 Mix: Not Applicable
Current as of January 3, 2013 2:22 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 712